• 1
    Third Report of the National Cholesterol Education Program. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 106: 31433421 (2002).
  • 2
    Grundy, S. M., Brewer, H. B. Jr, Cleeman, J. I., Smith, S. C. Jr, Lenfant, C. (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109: 433438.
  • 3
    Grundy, SM. (1997) Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. Circulation 95: 14.
  • 4
    Austin, M. A., Breslow, J. L., Hennekens, C. H., Buring, J. E., Willett, W. C., Krauss, RM. (1988) Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 260: 19171921.
  • 5
    Hulthe, J., Bokemark, L., Wikstrand, J., Fagerberg, B. (2000) The metabolic syndrome, LDL particle size, and atherosclerosis: the Atherosclerosis and Insulin Resistance (AIR) study. Arterioscler Thromb Vasc Biol. 20: 21402147.
  • 6
    Morton, RE. (1999) Cholesteryl ester transfer protein and its plasma regulator: lipid transfer inhibitor protein. Curr Opin Lipidol. 10: 321327.
  • 7
    Lagrost, L., Gandjini, H., Athias, A., Guyard-Dangremont, V., Lallemant, C., Gambert, P. (1993) Influence of plasma cholesteryl ester transfer activity on the LDL and HDL distribution profiles in normolipidemic subjects. Arterioscler Thromb. 13: 815825.
  • 8
    Arai, T., Yamashita, S., Hirano, K., et al (1994) Increased plasma cholesteryl ester transfer protein in obese subjects: a possible mechanism for the reduction of serum HDL cholesterol levels in obesity. Arterioscler Thromb. 14: 11291136.
  • 9
    Ebenbichler, C. F., Laimer, M., Kaser, S., et al (2002) Relationship between cholesteryl ester transfer protein and atherogenic lipoprotein profile in morbidly obese women. Arterioscler Thromb Vasc Biol. 22: 14651469.
  • 10
    Esterbauer, H., Schneitler, C., Oberkofler, H., et al (2001) A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet. 28: 178183.
  • 11
    Friedewald, W. T., Levy, R. I., Fredrickson, DS. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 18: 499502.
  • 12
    Krauss, R. M., Burke, DJ. (1982) Identification of multiple subclasses of plasma low density lipoproteins in normal humans. J Lipid Res. 23: 97104.
  • 13
    Ritsch, A., Ebenbichler, C., Naschberger, E., et al (2004) Phage-displayed recombinant single-chain antibody fragments with high affinity for cholesteryl ester transfer protein (CETP): cDNA cloning, characterization and CETP quantification. Clin Chem Lab Med. 42: 247255.
  • 14
    Grundy, S. M., Brewer, H. B. Jr, Cleeman, J. I., Smith, S. C. Jr, Lenfant, C. (2004) Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Arterioscler Thromb Vasc Biol. 24: e13e18.
  • 15
    St-Pierre, A. C., Cantin, B., Dagenais, G. R., et al (2005) Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec cardiovascular study. Arterioscler Thromb Vasc Biol. 25: 553559.
  • 16
    Hulthe, J., Wiklund, O., Bondjers, G., Wikstrand, J. (2000) LDL particle size in relation to intima-media thickness and plaque occurrence in the carotid and femoral arteries in patients with hypercholesterolaemia. J Intern Med. 248: 4252.
  • 17
    Gordon, D. J., Probstfield, J. L., Garrison, R. J., et al (1989) High-density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation 79: 815.
  • 18
    Robins, S. J., Collins, D., Wittes, J. T., et al (2001) Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 285: 15851591.
  • 19
    Brewer, H. B. Jr (2004) High-density lipoproteins: a new potential therapeutic target for the prevention of cardiovascular disease. Arterioscler Thromb Vasc Biol. 24: 387391.
  • 20
    Barter, P. J., Nicholls, S., Rye, K. A., Anantharamaiah, G. M., Navab, M., Fogelman, AM. (2004) Antiinflammatory properties of HDL. Circ Res. 95: 764772.
  • 21
    Barter, P. J., Baker, P. W., Rye, KA. (2002) Effect of high-density lipoproteins on the expression of adhesion molecules in endothelial cells. Curr Opin Lipidol. 13: 285288.
  • 22
    Ritsch, A., Patsch, J.R. (2003) Cholesteryl ester transfer protein: gathering momentum as a genetic marker and as drug target. Curr Opin Lipidol. 14: 173179.
  • 23
    Boekholdt, S. M., Sacks, F. M., Jukema, J. W., et al (2005) Cholesteryl ester transfer protein TaqIB variant, high-density lipoprotein cholesterol levels, cardiovascular risk, and efficacy of pravastatin treatment: individual patient meta-analysis of 13, 677 subjects. Circulation 111: 278287.
  • 24
    Guerin, M., Le Goff, W., Lassel, T. S., Van Tol, A., Steiner, G., Chapman, MJ. (2001) Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia. Arterioscler Thromb Vasc Biol. 21: 282288.
  • 25
    Guerin, M., Egger, P., Soudant, C., et al (2002) Cholesteryl ester flux from HDL to VLDL-1 is preferentially enhanced in type IIB hyperlipidemia in the post-prandial state. J Lipid Res. 43: 16521660.
  • 26
    Mann, C. J., Yen, F. T., Grant, A. M., Bihain, BE. (1991) Mechanism of plasma cholesteryl ester transfer in hypertriglyceridemia. J Clin Invest. 88: 20592066.
  • 27
    Foger, B., Ritsch, A., Doblinger, A., Wessels, H., Patsch, J.R. (1996) Relationship of plasma cholesteryl ester transfer protein to HDL cholesterol: studies in normotriglyceridemia and moderate hypertriglyceridemia. Arterioscler Thromb Vasc Biol. 16: 14301436.
  • 28
    Riemens, S., van Tol, A., Sluiter, W., Dullaart, R. (1998) Elevated plasma cholesteryl ester transfer in NIDDM: relationships with apolipoprotein B-containing lipoproteins and phospholipid transfer protein. Atherosclerosis 140: 7179.
  • 29
    Hogue, J. C., Lamarche, B., Gaudet, D., et al (2004) Relationship between cholesteryl ester transfer protein and LDL heterogeneity in familial hypercholesterolemia. J Lipid Res. 45: 10771083.
  • 30
    Ritsch, A., Drexel, H., Amann, F. W., Pfeifhofer, C., Patsch, J.R. (1997) Deficiency of cholesteryl ester transfer protein: description of the molecular defect and the dissociation of cholesteryl ester and triglyceride transport in plasma. Arterioscler Thromb Vasc Biol. 17: 34333441.
  • 31
    Bisgaier, C. L., Siebenkas, M. V., Brown, M. L., et al (1991) Familial cholesteryl ester transfer protein deficiency is associated with triglyceride-rich low density lipoproteins containing cholesteryl esters of probable intracellular origin. J Lipid Res. 32: 2133.
  • 32
    Sakai, N., Matsuzawa, Y., Hirano, K., et al (1991) Detection of two species of low density lipoprotein particles in cholesteryl ester transfer protein deficiency. Arterioscler Thromb. 11: 7179.
  • 33
    Grundy, S. M., Cleeman, J. I., Merz, C. N., et al (2004) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Arterioscler Thromb Vasc Biol. 24: e149e161.
  • 34
    Maumus, S., Marie, B., Siest, G., Visvikis-Siest, S. (2005) A Prospective Study on the Prevalence of Metabolic Syndrome Among Healthy French Families: two cardiovascular risk factors (HDL cholesterol and tumor necrosis factor-[alpha]) are revealed in the offspring of parents with metabolic syndrome. Diabetes Care 28: 675682.
  • 35
    Jones, P. H., Davidson, M. H., Stein, E. A., et al (2003) Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 92: 152160.
  • 36
    Brousseau, M. E., Schaefer, E. J., Wolfe, M. L., et al (2004) Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 350: 15051515.
  • 37
    Clark, R. W., Sutfin, T. A., Ruggeri, R. B., et al (2004) Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: an initial multidose study of torcetrapib. Arterioscler Thromb Vasc Biol. 24: 490497.
  • 38
    Okamoto, H., Iwamoto, Y., Maki, M., Sotani, T., Yonemori, F., Wakitani, K. (2003) Effect of JTT-705 on cholesteryl ester transfer protein and plasma lipid levels in normolipidemic animals. Eur J Pharmacol. 466: 147154.
  • 39
    Zhang, B., Fan, P., Shimoji, E., et al (2004) Inhibition of cholesteryl ester transfer protein activity by JTT-705 increases apolipoprotein E-containing high-density lipoprotein and favorably affects the function and enzyme composition of high-density lipoprotein in rabbits. Arterioscler Thromb Vasc Biol. 24: 19101915.
  • 40
    Dusserre, E., Moulin, P., Vidal, H. (2000) Differences in mRNA expression of the proteins secreted by the adipocytes in human subcutaneous and visceral adipose tissues. Biochim Biophys Acta. 1500: 8896.